AVA6000 Phase 1b expansion cohorts enrolling with data targeted for later in 2025 AVA6103 IND-enabling studies underway with a Phase 1 trial anticipated to begin in the first quarter of 2026 Multiple ...

Vivesto AB, an oncology-focused development company, today announced that it has signed an agreement with the Australian pharmaceutical company Kazia Therapeutics to acquire ...